• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail


Cytosol Labs and Medcomp are voluntarily recalling triCitrasol, an unapproved product that has been used to keep bloodlines open and may cause death when infused into patients. FDA has learned that a patient died of cardiac arrest shortly after triCitrasol, a 46.7% concentration of sodium citrate anticoagulant, was injected full strength into a hemodialysis permanent blood access catheter that had just been implanted. Rapid or excessive infusion of citrate solutions can cause fatal heart arrhythmias, seizures or bleeding due to loss of blood calcium.